The PRISMAP project
PRISMAP - The European medical isotope programme: Production of high purity isotopes by mass separation.
PRISMAP is the European medical radionuclide programme on the production of high purity radionuclides (radioactive isotopes) by mass separation. It creates the European consortium of the key intense neutron sources, isotope mass separation facilities and high-power accelerators and cyclotrons, with leading biomedical and healthcare research institutes in the active translation of the emerging radionuclides into medical diagnosis and treatment.
PRISMAP goal is to create a single-entry point for a fragmented user community distributed amongst universities, research centers, industry and hospitals, in a similar way as how the National Isotope Development Center NIDC, supported by the Department of Energy (DOE), has provided radionuclide sources for users in the USA.
PRISMAP brings together a consortium of 23 beneficiaries from 13 countries, one European Research Laboratory and an International Organisation. It receives the support of leading associations and institutions in the field such as the European Association of Nuclear Medicine (EANM) and the International Atomic Energy Agency (IAEA).
The project goal is to provide a sustainable source of high purity grade new radionuclides for medicine, involving from the onset upcoming major European infrastructures, to provide a single-entry point for all researchers active in this field including SMEs, global pharma, nuclear centres, hospitals and universities, using standardized access procedures.
The new isotope enrichment and standardization techniques triggered in PRISMAP will expand its services and provide them to yet unreachable remote European laboratories. PRISMAP thus strives to create a paradigm shift in the early phase research on radiopharmaceuticals, targeted drugs for cancer – one of the major diseases in Europe – theranostics and personalised medicine, shaping the European isotope landmark as a gold standard to accelerate the development of the pharma industry and ultimately of better healthcare for the improvement of humans life.
▪Provide access to new radionuclides and new purity grades for the medical research;
▪Create a common entry port and web interface to the starting research community;
▪Enhance the clarity and regulatory procedures to enhance research with radiopharmaceuticals;
▪Improve the delivered radionuclide data and regulation, along with biomedical research capacity;
▪Ensure sustainability of PRISMAP on the long term;
Notably, PRISMAP addresses cancer which is a major societal challenge as recently reconfirmed by Europe’s Beating Cancer Plan.
Duration: 1 May 2021 r. – 30 April 2025 r. (48 months)
Funded under: European Union's Horizon 2020 research and innovation programme
EU contribution: 4 995 257,50 EUR
NCBJ contribution: 321 125,00 EUR
The coordinator of the project: prof. Renata Mikołajczak
Project website: www.prismap.eu